§ 830.20 Requirements for a unique device identifier.

A unique device identifier (UDI) must:

(a) Be issued under a system operated by FDA or an FDA-accredited issuing agency;

(b) Conform to each of the following international standards:

(1) ISO/IEC 15459–2:2006(E), Information technology—Unique identifiers—Part 2: Registration procedures (second edition; March 1, 2006), into §§ 830.20(b) and 830.100(b);

(2) ISO/IEC 15459–4:2008(E), Information technology—Unique identifiers—Part 4: Individual items (second edition; July 15, 2008), into §§ 830.20(b) and 830.100(b);

(3) ISO/IEC 15459–6:2007(E), Information technology—Unique identifiers—Part 6: Unique identifier for product groupings (first edition; June 15, 2007), into §§ 830.20(b) and 830.100(b).

§ 830.40 Use and discontinuation of a device identifier.

(a) Only one device identifier from any particular system for the issuance of unique device identifiers (UDIs) may be used to identify a particular version or model of a device. A particular version or model may be identified by UDIs from two or more systems for the issuance of UDIs.

(b) A device identifier shall be used to identify only one version or model.

(c) In the event that a version or model of a device is discontinued, its device identifier may not be reassigned to another device. If a discontinued version or model is re-introduced and no changes have been made that would require the use of a new device identifier, the device identifier that was previously in use may be used to identify the device.

(d) In the event that an issuing agency relinquishes or does not renew its accreditation, you may continue to use a previously issued UDI until such time as § 830.50 requires you to assign a new device identifier.

§ 830.50 Changes that require use of a new device identifier.

(a) Whenever you make a change to a device that is required to bear a unique device identifier (UDI) on its label, and the change results in a new version or model, you must assign a new device identifier to the new version or model.

(b) Whenever you create a new device package, you must assign a new device identifier to the new device package.

§ 830.60 Relabeling of a device that is required to bear a unique device identifier.

If you relabel a device that is required to bear a unique device identifier (UDI), you must:

(a) Assign a new device identifier to the device, and

(b) Keep a record showing the relationship of the prior device identifier to your new device identifier.

§ 830.100 FDA accreditation of an issuing agency.

(a) Eligibility. A private organization may apply for accreditation as an issuing agency.
Food and Drug Administration, HHS § 830.110

(b) Accreditation criteria. FDA may accredit an organization as an issuing agency, if the system it will operate:
(1) Will employ unique device identifiers (UDIs) that meet the requirements of this part to adequately identify a device through its distribution and use;
(2) Conforms to each of the following international standards:
   (i) ISO/IEC 15459–2, which is incorporated by reference at §830.10;
   (ii) ISO/IEC 15459–4, which is incorporated by reference at §830.10;
   (iii) ISO/IEC 15459–6, which is incorporated by reference at §830.10.
(3) Uses only characters and numbers from the invariant character set of ISO/IEC 646, which is incorporated by reference at §830.10.
(4) Will be available to all users according to a single set of consistent, fair, and reasonable terms and conditions.
(5) Will protect against conflicts of interest between the issuing agency (and its officers, employees, and other agents) and labelers (and their officers, employees, and other agents) seeking to use UDIs that may impede the applicant’s ability to independently operate a fair and neutral identifier system.

§ 830.110 Application for accreditation as an issuing agency.

(a) Application for initial accreditation.
(1) An applicant seeking initial FDA accreditation as an issuing agency shall notify FDA of its desire to be accredited by sending a notification by email to udi@fda.hhs.gov, or by correspondence to: UDI Regulatory Policy Support, Center for Devices and Radiological Health, Food and Drug Administration, Bldg. 66, Rm. 3303, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002.
(2) FDA will provide the applicant with additional information to aid in submission of an application for approval as an issuing agency, together with an email address for submission of an application.
(3) The applicant shall furnish to FDA, via email to the email address provided in paragraph (a)(1) of this section, an application containing the following information, materials, and supporting documentation:
   (i) Name, address, and phone number of the applicant;
   (ii) Detailed descriptions of any standards or criteria the applicant will apply to participating labelers;
   (iii) A detailed description of the guidelines that govern assignment of a unique device identifier (UDI) to a device;
   (iv) A detailed description of the review and decisionmaking process the applicant will apply when determining whether a particular labeler may use the applicant’s UDI system, including:
      (A) Copies of the application forms, guidelines, instructions, and other materials the applicant will send to medical device labelers who wish to use the applicant’s unique device identification system;
      (B) Policies and procedures for notifying a labeler of deficiencies in its use of UDIs;
      (C) Procedures for monitoring a labeler’s correction of deficiencies in its use of UDIs;
      (D) Policies and procedures for suspending or revoking a labeler’s use of the applicant’s UDI system, including any appeals process;
      (v) Description of the applicant’s electronic data management system with respect to its review and decision processes and the applicant’s ability to provide electronic data in a format compatible with FDA data systems;
      (vi) Fee schedules, if any, together with an explanation of any fee waivers or reductions that are available;
      (vii) Detailed information regarding any financial or other relationship between the applicant and any labeler(s) or governmental entity(ies); and
      (viii) Other information required by FDA to clarify the application for accreditation.

(1) At least 9 months before the date of expiration of its accreditation, an issuing agency shall inform FDA, at the address given in paragraph (a)(1) of